Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Borchmann

Showing results (111-120 of 252) with videos related to

Pageof 26
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2005
Treatment of refractory Hodgkin's lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibodyRoland Schnell, Markus Dietlein, Jan Oliver Staak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 28, 2017
Late Relapse of Classical Hodgkin Lymphoma: An Analysis of the German Hodgkin Study Group HD7 to HD12 TrialsPaul J Bröckelmann, Helen Goergen, Charlotte Kohnhorst, et al.
Blood|July 13, 2012
Brentuximab vedotin for relapsed or refractory CD30+ hematologic malignancies: the German Hodgkin Study Group experienceAchim Rothe, Stephanie Sasse, Helen Goergen, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 31, 2022
Salvage High-dose Melphalan With Autologous Stem cell Transplantation as Bridge to Consolidation Therapy for Chemoresistant Aggressive B-cell LymphomaDominic Kaddu-Mulindwa, Philipp Gödel, Nadine Kutsch, et al.
Blood|July 26, 2003
The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity against malignant lymphomaPeter Borchmann, John F Treml, Hinrich Hansen, et al.
Leukemia|December 17, 2024
T-cell diversity and exclusion of blood-derived T-cells in the tumor microenvironment of classical Hodgkin LymphomaNicole Seifert, Sarah Reinke, Johanna Grund, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 26, 2013
Treatment-related mortality in patients with advanced-stage hodgkin lymphoma: an analysis of the german hodgkin study groupDiana Wongso, Michael Fuchs, Annette Plütschow, et al.
Leukemia|October 10, 2021
Clinical outcomes of relapsed and refractory Hodgkin lymphoma patients after contemporary first-line treatment: a German Hodgkin Study Group analysisPaul J Bröckelmann, Horst Müller, Sarah Gillessen, et al.
BMC Cancer|June 18, 2022
Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin Lymphoma - Data from the prospective, multicenter phase III HD16 trialLutz van Heek, Colin Stuka, Helen Kaul, et al.
British Journal of Haematology|December 20, 2021
Impact of bone marrow involvement on early positron emission tomography response and progression-free survival in the HD18 trial for patients with advanced-stage Hodgkin lymphomaStefanie Kreissl, Conrad-Amadeus Voltin, Helen Kaul, et al.
Pageof 26

Showing results (111-120 of 252) with videos related to

Sort By:
Pageof 26
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2005
Treatment of refractory Hodgkin's lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibodyRoland Schnell, Markus Dietlein, Jan Oliver Staak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 28, 2017
Late Relapse of Classical Hodgkin Lymphoma: An Analysis of the German Hodgkin Study Group HD7 to HD12 TrialsPaul J Bröckelmann, Helen Goergen, Charlotte Kohnhorst, et al.
Blood|July 13, 2012
Brentuximab vedotin for relapsed or refractory CD30+ hematologic malignancies: the German Hodgkin Study Group experienceAchim Rothe, Stephanie Sasse, Helen Goergen, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 31, 2022
Salvage High-dose Melphalan With Autologous Stem cell Transplantation as Bridge to Consolidation Therapy for Chemoresistant Aggressive B-cell LymphomaDominic Kaddu-Mulindwa, Philipp Gödel, Nadine Kutsch, et al.
Blood|July 26, 2003
The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity against malignant lymphomaPeter Borchmann, John F Treml, Hinrich Hansen, et al.
Leukemia|December 17, 2024
T-cell diversity and exclusion of blood-derived T-cells in the tumor microenvironment of classical Hodgkin LymphomaNicole Seifert, Sarah Reinke, Johanna Grund, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 26, 2013
Treatment-related mortality in patients with advanced-stage hodgkin lymphoma: an analysis of the german hodgkin study groupDiana Wongso, Michael Fuchs, Annette Plütschow, et al.
Leukemia|October 10, 2021
Clinical outcomes of relapsed and refractory Hodgkin lymphoma patients after contemporary first-line treatment: a German Hodgkin Study Group analysisPaul J Bröckelmann, Horst Müller, Sarah Gillessen, et al.
BMC Cancer|June 18, 2022
Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin Lymphoma - Data from the prospective, multicenter phase III HD16 trialLutz van Heek, Colin Stuka, Helen Kaul, et al.
British Journal of Haematology|December 20, 2021
Impact of bone marrow involvement on early positron emission tomography response and progression-free survival in the HD18 trial for patients with advanced-stage Hodgkin lymphomaStefanie Kreissl, Conrad-Amadeus Voltin, Helen Kaul, et al.
Pageof 26